The Danish biotech company Curasight has developed an imaging technology that provides less evasive and improved diagnosis of multiple cancers. Their team are the pioneers behind the novel uPAR Theranostics technology – a technology that minimises irradiation of healthy tissue by combining targeted uTREAT® radiation therapy, with precision uTRACE® diagnostics. Several clinical studies are in phase II, in partnership with Rigshospitalet – the Danish University Hospital of Copenhagen.
Challenge
When Curasight made the decision to go public via an Initial Public Offering (IPO), there were several things that had to be put in place to ensure full compliance and to enable them to communicate effectively and efficiently with investors and journalists. The listing process not only meant meeting regulatory requirements but also addressing new stakeholders' expectations.
Their existing website was not fit for the purpose of being able to handle the requirements of a listed company, and they also needed a new 'Investor Relations' section to present the financial and regulatory information required for going public.